Grail Inc (GRAL)

$GRAL Bottomline, it's a novel, first of its kind lab test and not a treatment for cancer. Clinical evidence points to high reliability and validity. While it failed its primary end point for UK NHS clinical utility trial, it did achieve a significant 20% reduction in stage 4 cancers via early detection and met all 3 secondary end points. Evidence points to growing adoption via private payors, Tricare and private partnerships (HIMS, Samnsung, etc). Why be a nervous Nellie? I have no doubt ADcom experts will recommend approval with guidance to contune post marketing surveliance and addtional studies to guide broader adoption. Start slow and add speed with better visibility. Do your own DD.

$GRAL It will be very interesting if most investors think that an AdCom is only being held because there is some specific problem with test. For a first-of-its-kind device in a genuinely new category, an AdCom can also be part of establishing the regulatory framework and evaluating a technology the FDA has never reviewed before. If the market is broadly interpreting the AdCom itself as evidence of a problem, that could create a very interesting setup.

$GRAL $GRAL If Galleri receives FDA approval, the size of the opportunity changes immediately. The real Galleri opportunity is far larger than the U.S. Our demographic estimate puts the 50+ population at roughly 125M in the U.S., ~300M in Europe and >1.1B in Asia. At just 5% penetration, that is 75M+ potential annual tests — before Latin America or other markets. At 400$ per test it is 28 bil $ revenue.

$GRAL NHS wont use this but USA might. Wont go crazy here.

$GRAL @Monkey7779192 Keep in mind what i said in an earlier post : If the FDA does not approve the test to be covered by medicare Look out below . The 52 week range is $36-$118. I see a lot of options ( both calls and puts ) for Oct . I think they are having independent scientists coming in on 9/23/26 which works with the FDA . I actuall y got an email from Galleri saying my last test was 5/4/24 and of course suggest i should take another . more info on Galleri.com or (833) 694-2553

$TNXP We break $14.33 fib level next week and test the next fib at $21.19 (78.6 level). The RSI is so beat down on this and the EMA's are ready for a spring back! $TNON $GRAL $SLS

$TNXP This is bottom today boys and girls. I loaded more on my long and started a big swing position here today. $TNON $GRAL

$GRAL Gemini's current Galleri Multi-Cancer Early Detection Test coverage summary. See 3rd entry below. The bill by Congress shows the government would like more data before recommending medicare reimbursement... Current Coverage StatusOut-of-Pocket Cost: Without insurance coverage, the standard list price for the Galleri test is typically $949, though discounts or promotional pricing are sometimes available. [1] (https://www.galleri.com/patient/the-galleri-test) Limited Exceptions: A few select health plans cover the test. For example, TRICARE covers the test for eligible military beneficiaries aged 50 and older with an elevated risk for cancer. A small number of commercial or regional insurers (such as Priority Health or Curative) have added coverage for specific Medicare Advantage or self-insured employer group plans. [1] (https://www.galleri.com/get-started/patients), [2] (https://grail.com/press-releases/priority-health-collaborates-with-grail-as-the-first-michigan-health-plan-to-offer-the-galleri-multi-cancer-early-detection-blood-test-to-employer-plans/), [3] (https://grail.com/press-releases/curative-insurance-company-adds-grails-galleri-test-to-member-benefits-for-multi-cancer-early-detection/) Future Medicare Reimbursement: Congress passed a law allowing Medicare to begin reimbursing multi-cancer early detection (MCED) tests starting in 2028, pending broader federal approvals and guideline updates

$GRAL Volume is low and not much options flow. Its possible the adcom wont be that important.

$GRAL @SunAndStorm I took the test and for $750 i felt it was well worth it . Hell knows how many times I lost 10x that trading in a day. BTW some Dr. charge $1000 . However I know a woman who had Breast Cancer and Between surgery , Chemo , Radiation Etc. Her bill was over $300K . That was over ten years ago . This test is supposed to detect Cancer in a very early stage as I understand it . I own the stock and Calls . If the FDA does not approve it , Look out below !

$GRAL Options pricing suggesting it may move 30 percent up or down. Kinda disappointing.

$GRAL Question on Galleri Cancer Screening Test approval from @Monkey7779192 from FDA. The test attempts to diagnose the presence of 51 different cancers and beat clinical testing alone that tends to pick up earlier cancers better, because they are not seeding the blood with enough tumor DNA, because they have not invaded the tissue enough among other possible factors.... Formal FDA review is on Sept. 23rd. Hard to say how they will vote. It depends on whether they determine it is cost effective. The increased pickup in early dx is between 16% and 19% depending on whether you look at Stage I and II patients vs. Stages I -III patients. So if you screen the entire pop. to pick that up, is it cost effective? That will drive the approval or non-approval. Cancer drugs that only extend life by 4 months get approved, so it could happen to this diagnostic test for cancer. At ~$750 per test, running standard annual screening across a population requires roughly $350,000+ in pure testing costs alone to pick up a single early-stage cancer. (that's from Gemini's analysis) The test also has the ability to pick up cancers for where there is no screening, for example... Esophageal Cancer: 57.1% drop in Stage IV diagnoses during follow-up rounds. Colorectal Cancer: 34.4% drop in Stage IV diagnoses during follow-up rounds. This means that it could break out testing subsets of patients who have risk factors for esophageal and the other essentially unscreenable cancers and offer specific vs. buckshot testing for all common cancers. I worked with Gemini to look at the data on the total group of G-Test Pos. Clinical Neg. patients, meaning their cancers were missed by clinicians. Note that 82% of these remain unsolved in terms of IDing a clinically evident tumor. Longer term follow-up will be required to see how many of these are just "early detection." In other words, the results could improve further over time... The table shows the breakdown of tumors detected on follow-up from this G--Test Positive Clinically Negative subgroup by Stage... IMO.

$GRAL Options premium seems reasonable cheap if this will either drop to below 50 or pop above 110 after the adcom.

$GRAL I think that European bad report has been holding this down. And we hope FDA doesn’t concur with Europe. If not SP will go to $10.00 and I have a shItload. Trust Me

$GRAL easily moves on small volume. I suspect beacuse of 35 float which is relatively low. I want to take position but the september 14 presentation puts me off.

$GRAL If investors don’t understand the difference between a typical drug AdCom and a first-of-a-kind PMA device panel, they may wrongly assume FDA called the panel because it found a problem with the application. That may often be the case with drug AdComs. It is not the case with GRAIL’s Galleri. Galleri is a first-of-a-kind medical device, and its advisory panel is part of the normal PMA review process for this type of device. That distinction matters.

$GRAL I doubt many short funds fully understand how much the baseline round distorted the pooled NHS-Galleri result. When they eventually recognize it and start covering, that could become a major event for the stock.

$GRAL $GRAL The market may be misunderstanding the NHS-Galleri trial. The baseline and incident rounds measure very different things. Baseline includes cancers that may have been developing for years before screening began. The later rounds measure the effect of repeated annual screening on newly diagnosed late-stage cancers. These rounds therefore have opposite criteria for success: in the baseline round, a larger number of true cancers detected is a better result; in the subsequent incident rounds, a smaller number of late-stage cancers diagnosed is a better result The test is therefore statistically penalised for doing exactly what an effective screening test should do: detecting clinically important cancers earlier.

$GRAL MENLO PARK, Calif. , Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m. ET .

$TNXP I'll buy more today and tomorrow. I'm not missing the break over $15. I didn't have as much $GRAL at $15 - $17 before it ran. I'm not messing around with this one.

$TNXP Over $14.30 shorts will cover and this will start its $GRAL type run. Big move coming to fill gaps at $20.77 and $59.